Up to 1100 more staff face redundancy in ongoing restructuring plan

US biotech heavyweight Amgen is to cut an extra 600–1100 jobs by the end of 2015, on top of the 2900 the company earmarked for the chop in August.

These cuts will mean that, overall, Amgen will be shedding 20% of its global workforce and closing sites in Seattle and Colorado, concentrating its presence in the US’s growing pharma hubs of south San Francisco and the Boston–Cambridge area.

The primary motivation for the cuts seems to be cost-cutting to satisfy shareholders. Amgen claims that its overall restructuring plan will save the company up to $1.5 billion (£928 million) a year.